Takenaka K, Minami T, Yoshihashi Y, Hirata S, Kimura Y, Kono H.

Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.

Nakata H, Maeda K, Das D, Chang SB, Matsuda K, Rao KV, Harada S, Yoshimura K, Ghosh AK, Mitsuya H.

Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.

Sci Rep. 2019 Mar 18;9(1):4828. doi: 10.1038/s41598-019-41080-w. PMID: 30886166; PMCID: PMC6423129

https://pubmed.ncbi.nlm.nih.gov/30886166/

Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K J, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

Potential role for secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.

Ikebe E, Matsuoka S, Tanaka A, Yonemura Y, Fujii Y, Ohsaka A, Okazaki H, Kitazawa J, Ohtani S, Nakayama T, Momose S, Miwa I, Taira R, Yoyota K, Kino S, Kato H, Hamaguchi I.

Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan- A retrospective multicenter study.

Transfusion and Apheresis Science .2019 Apr;58(2):162-168.  PMID: 30670326

https://pubmed.ncbi.nlm.nih.gov/30670326/

Shirayama R, Takedani H, Chikasawa Y, Ishiguro A, Ishimura M, Isobe K, Uchiba M, Ogata Y, Kakuda H, Kusuhara K, Shirahata A.

Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.

Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C.

JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM)

Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).